Ebb & Flow

Speculators start your engines. Last week saw developments in the insomnia space that have analysts and investors pondering the futures of Sepracor (SEPR) and Neurocrine (NBIX).

SEPR started the week with a 9% pop on Monday following media reports that Pfizer (PFE) might have its eye on acquiring the company and in particular SEPR's Lunesta insomnia drug. Further fueling the fire were analyst notes that also threw Schering-Plough (SGP) into the mix as a potential suitor. ...